Methods for treating apnea, apnea disorders, and other disorders using optically pure (-) norcisapride

A method of treating disorders mediated by vagal activity in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of treating irritable bowel syndrome in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of treating bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of treating asthma in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of treating urinary incontinence in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of treating apnea or apnea disorders in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing bulimia in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing disorders mediated by vagal activity in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing irritable bowel syndrome in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing asthma in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing urinary incontinence in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.

A method of preventing or managing apnea or apnea disorders in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (−) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer.